Myomo said today it filed with the SEC for an initial public offering, looking to register on the NYSE under the ticker symbol “MYO”.
Myomo develops and produces myoelectric orthotics for patients with neuromuscular disorders, including its flagship MyoPro line. The orthosis devices are non-invasive, powered braces used to support weak or deformed arms and hands to allow for functional activity.
The Cambridge, Mass.-based company has not yet stated how many shares it plans to offer or any of the pricing for the shares.
Funds from the IPO are slated to support sales and marketing expansion, as well as product development, debt repayment and for working capital and general corporate purposes.
Tripoint Global Equities and its online Banq division are acting as lead managingselling agent and book runner for the offering, according to a press release.